AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...

In a split decision, a federal jury in Chicago ordered AbbVie to pay $150 million in punitive damages for fraudulently misrepresenting the risks of its AndroGel testosterone replacement drug. But at ...

AbbVie took a damaging hit Monday as the first verdict from a series of bellwether AndroGel cases went against the drugmaker to the tune of $150 million. Jurors decided after hearing weeks of ...

On Monday, lawyers for AndroGel maker AbbVie will present their selection of 16 plaintiffs they’d like to represent the growing class of men who are suing the company over allegations that its product ...

(Bloomberg) — Abbott Laboratories and AbbVie Inc., the company it spun off last year, hid the dangers of using the testosterone replacement drug AndroGel, five men claimed in lawsuits. Their ...

Thousands of federal lawsuits alleging harm from AbbVie’s AndroGel are on the cusp of being settled, marking the end of a long legal saga about the safety of testosterone therapy and the marketing ...

Are you a male experiencing symptoms of low testosterone such as weight gain and a high-pitched voice? If so, you may want to look into a product by the name of AndroGel. This testosterone gel has ...

AbbVie’s former blockbuster testosterone-replacement treatment AndroGel will be at the center of a class action lawsuit set to go to trial this year, alleging, in short, that previously healthy men ...

The trial was the first in an estimated 6,000 lawsuits that the drug maker faces over its controversial marketing for its testosterone treatment. In a split decision, a federal jury in Chicago ordered ...